Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PET with [18F]Flumazenil As an Index of Neurodegeneration in MS: Sensitivity At an Early Disease Stage and Pathophysiological Meaning

NCT03825601 is registered in ClinicalTrials.gov with Institut National de la Santé Et de la Recherche Médicale, France as lead sponsor.

NCT NCT03825601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03825601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PET with [18F]Flumazenil As an Index of Neurodegeneration in MS: Sensitivity At an Early Disease Stage and Pathophysiological Meaning
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Phase
Not applicable
Overall status
Completed
Start date
May 2, 2019
Completion date
August 26, 2024
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing-remitting multiple sclerosis